2V13

Crystal Structure of Renin with Inhibitor 7


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Work: 0.228 
  • R-Value Observed: 0.228 

wwPDB Validation   3D Report Full Report


This is version 1.5 of the entry. See complete history


Literature

Structure-Based Drug Design: The Discovery of Novel Nonpeptide Orally Active Inhibitors of Human Renin

Rahuel, J.Rasetti, V.Maibaum, J.Rueger, H.Goschke, R.Cohen, N.C.Stutz, S.Cumin, F.Fuhrer, W.Wood, J.M.Grutter, M.G.

(2000) Chem Biol 7: 493

  • DOI: https://doi.org/10.1016/s1074-5521(00)00134-4
  • Primary Citation of Related Structures:  
    2V0Z, 2V10, 2V11, 2V12, 2V13, 2V16

  • PubMed Abstract: 
  • The aspartic proteinase renin plays an important physiological role in the regulation of blood pressure. It catalyses the first step in the conversion of angiotensinogen to the hormone angiotensin II. In the past, potent peptide inhibitors of renin have been developed, but none of these compounds has made it to the end of clinical trials ...

    The aspartic proteinase renin plays an important physiological role in the regulation of blood pressure. It catalyses the first step in the conversion of angiotensinogen to the hormone angiotensin II. In the past, potent peptide inhibitors of renin have been developed, but none of these compounds has made it to the end of clinical trials. Our primary aim was to develop novel nonpeptide inhibitors. Based on the available structural information concerning renin-substrate interactions, we synthesized inhibitors in which the peptide portion was replaced by lipophilic moieties that interact with the large hydrophobic S1/S3-binding pocket in renin.


    Related Citations: 
    • The Crystal Structures of Recombinant Glycosylated Human Renin Alone and in Complex with a Transition State Analog Inhibitor.
      Rahuel, J., Priestle, J.P., Grutter, M.G.
      (1991) J Struct Biol 107: 227

    Organizational Affiliation

    Core Technology Area, Novartis Pharma AG, Metabolic and Cardiovascular Diseases, Basle, Switzerland.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
RENIN340Homo sapiensMutation(s): 0 
Gene Names: REN
EC: 3.4.23.15
UniProt & NIH Common Fund Data Resources
Find proteins for P00797 (Homo sapiens)
Explore P00797 
Go to UniProtKB:  P00797
PHAROS:  P00797
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP00797
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
C40
Query on C40

Download Ideal Coordinates CCD File 
B [auth A]N-[(2R,4S,5S,7R)-4-AMINO-8-(BUTYLAMINO)-5-HYDROXY-2,7-DIMETHYL-8-OXOOCTYL]-2-(3-METHOXYPROPOXY)BENZAMIDE
C25 H43 N3 O5
HCEVFKSMFFEYMG-WKDRNLAYSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
C40 BindingDB:  2V13 IC50: 22 (nM) from 1 assay(s)
PDBBind:  2V13 IC50: 26 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Work: 0.228 
  • R-Value Observed: 0.228 
  • Space Group: P 41 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 98.4α = 90
b = 98.4β = 90
c = 95.6γ = 90
Software Package:
Software NamePurpose
X-PLORrefinement
MADNESSdata reduction

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2008-07-08
    Type: Initial release
  • Version 1.1: 2011-05-08
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2017-06-28
    Changes: Data collection
  • Version 1.4: 2017-07-12
    Changes: Refinement description
  • Version 1.5: 2019-04-03
    Changes: Data collection, Source and taxonomy